Science:Life Sciences
Though the year began with a banking crisis and has been marked with layoffs and restructurings, we have managed to avoid a feared recession. It’s been a big year for new drug approvals, M&A activity has been brisk, and biotech stocks have rallied in recent weeks pushing the widely watched S&P biotech index into positive territory. We continue our annual tradition to look back across the year in biotech and ahead to JPMorgan and beyond with Adam Feuerstein, Polk award-winning journalist and senior biotech writer for STAT. We spoke to Feuerstein about the biotech news that shaped 2023, the year’s best and worst CEOs, and what’s ahead in 2024.
More Episodes
Democratizing Drug Discovery
2021-09-30
2021-09-30
Scaling Genetic Counseling Services with AI
2021-09-23
2021-09-23
Striking Hepatitis B at Its Core
2021-09-02
2021-09-02
Building a Better Path to Neurotherapeutics
2021-08-12
2021-08-12
Engineering Life to Reach New Worlds
2021-07-29
2021-07-29
Mapping the Universe of Human Proteins
2021-07-15
2021-07-15
A Test for Data-Driven Drug Development
2021-06-10
2021-06-10
Get this podcast on your
phone, FREE
